glp-1 and gip receptor agonist The Effects of Dual GLP-1/GIP Agonism on Glucagon Secretion—A Review The dual glucose-dependent insulinotropic polypeptide

A 17-month study specifically looking at its effect on obesity showed people on the highest dose of tirzepatide (15 milligrams) lost on average just over 20% of their body weight

Our study included any GLP-1 receptor agonists that were prescribed during the study period in Ontario, Canada

Its FDA-approved for weight management under the name Saxenda and is a proven option for those comfortable with daily administration

That is also completely normal

doi: 10.2337/cd19-0100

Published in 1993, this testing was overseen by Michael Nauck, a physician at the University of Gttingen in collaboration with Creutzfeldt, Holst and other colleagues